ABL1 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ABL1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

AFF1 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain AFF1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

BCR is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain BCR status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

DEK is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain DEK status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

ELL is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ELL status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

FLT3 is altered in 6.76% of T-cell lymphoblastic leukemia/lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain FLT3 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

KMT2A is altered in 5.63% of T-cell lymphoblastic leukemia/lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KMT2A status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

MECOM is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MECOM status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell lymphoblastic leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

MLLT10 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT10 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

MLLT3 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT3 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

MLLT4 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MLLT4 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for T-cell lymphoblastic leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NRIP3 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

NUP214 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NUP214 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

PBX1 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain PBX1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

RPN1 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain RPN1 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

TCF3 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TCF3 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].

TP53 is altered in 4.05% of T-cell lymphoblastic leukemia/lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [3].